Summary
Pfizer Inc. (PFE) announced the pricing of a significant public offering of senior unsecured notes totaling $5 billion. This offering includes various tranches with maturities ranging from 2022 to 2049 and coupon rates from 2.800% to 4.000%. The company utilized its existing shelf registration statement filed on February 26, 2018, to facilitate this debt issuance. This move allows Pfizer to secure long-term funding at a time of potentially favorable interest rates. Investors should note that this is a debt issuance and does not represent an equity offering. The primary purpose of such an issuance is typically to fund general corporate purposes, which could include strategic acquisitions, research and development, capital expenditures, or debt refinancing. The offering is expected to close on March 11, 2019.
Key Highlights
- 1Pfizer priced a $5 billion public offering of notes.
- 2The offering comprises multiple tranches with maturities from 3 years (2022) to 30 years (2049).
- 3Interest rates on the notes range from 2.800% to 4.000%.
- 4The issuance was made under Pfizer's existing shelf registration statement.
- 5The offering is expected to close on March 11, 2019.
- 6Key underwriters include Barclays Capital Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, and J.P. Morgan Securities LLC.
- 7This is a debt issuance, not an equity offering.